Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Capital Expenditures (2020 - 2022)

Rapid Therapeutic Science Laboratories' Capital Expenditures history spans 3 years, with the latest figure at -$315646.0 for Q4 2022.

  • For Q4 2022, Capital Expenditures changed N/A year-over-year to -$315646.0; the TTM value through Jun 2023 reached -$315645.0, down 169.8%, while the annual FY2022 figure was $39155.0, 86.62% down from the prior year.
  • Capital Expenditures for Q4 2022 was -$315646.0 at Rapid Therapeutic Science Laboratories, down from $1.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $319596.0 in Q2 2022 and bottomed at -$315646.0 in Q4 2022.
  • The 3-year median for Capital Expenditures is $35204.0 (2022), against an average of $42700.7.
  • The largest YoY upside for Capital Expenditures was 1497.98% in 2022 against a maximum downside of 100.0% in 2022.
  • A 3-year view of Capital Expenditures shows it stood at $135000.0 in 2020, then crashed by 42.67% to $77393.0 in 2021, then plummeted by 507.85% to -$315646.0 in 2022.
  • Per Business Quant, the three most recent readings for RTSL's Capital Expenditures are -$315646.0 (Q4 2022), $1.0 (Q3 2022), and $319596.0 (Q2 2022).